Enhancement of anti-tumor effect of antibody-drug conjugate in combination with nobiletin and other PMFs

被引：0
|
作者：
Masuoka, Tomoya [1 ]
Iwasawa, Takumi [1 ]
Yonezawa, Takayuki [2 ]
Watanabe, Akio [3 ]
Woo, Jetae [2 ]
Kato, Kazunori [1 ]
机构：
[1] Toyo Univ, Grad Sch Sci Eng, Tokyo, Japan
[2] Chubu Univ, Grad Sch Biotech, Kasugai, Aichi, Japan
[3] Jumonji Univ, Niiza, Saitama, Japan
来源：
CANCER SCIENCE | 2024年 / 115卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
J-1046
引用
收藏
页码：393 / 393
页数：1
相关论文
共 50 条
  • [31] STUDIES ON ENHANCEMENT OF ANTI-TUMOR EFFECT .3. INFLUENCE OF IPRONIAZID ON THE COMBINATION EFFECT OF RESERPINE WITH ANTI-TUMOR AGENTS ON L1210
    WAKUSAWA, S
    MIYAMOTO, K
    KOSHIURA, R
    GANN, 1982, 73 (04): : 637 - 641
  • [32] Targeting tumor lineage plasticity in hepatocellular carcinoma using an anti-CLDN6 antibody-drug conjugate
    Kong, Fan-En
    Li, Guang-Meng
    Tang, Yun-Qiang
    Xi, Shao-Yan
    Loong, Jane Ho Chun
    Li, Mei-Mei
    Li, Hao-Long
    Cheng, Wei
    Zhu, Wen-Jie
    Mo, Jia-Qiang
    Gong, Yuan-Feng
    Tang, Hui
    Zhao, Yue
    Zhang, Yan
    Ma, Stephanie
    Guan, Xin-Yuan
    Ma, Ning-Fang
    Xie, Mao-Bin
    Liu, Ming
    SCIENCE TRANSLATIONAL MEDICINE, 2021, 13 (579)
  • [33] Blockade of SIRPα-CD47 axis by anti-SIRPα antibody enhances anti-tumor activity of DXd antibody-drug conjugates
    Sue, Mayumi
    Tsubaki, Takuya
    Ishimoto, Yoko
    Hayashi, Shinko
    Ishida, Saori
    Otsuka, Takafumi
    Isumi, Yoshitaka
    Kawase, Yumi
    Yamaguchi, Junko
    Nakada, Takashi
    Ishiguro, Jun
    Nakamura, Kensuke
    Kawaida, Reimi
    Ohtsuka, Toshiaki
    Wada, Teiji
    Agatsuma, Toshinori
    Kawasaki, Norihito
    PLOS ONE, 2024, 19 (06):
  • [34] BRENTUXIMAB VEDOTIN Anti-CD30 Antibody-Drug Conjugate Oncolytic
    Copeland, A.
    Younes, A.
    DRUGS OF THE FUTURE, 2010, 35 (10) : 797 - 801
  • [35] PHARMACOKINETICS AND DISPOSITION OF AN ANTI-5T4 ANTIBODY-DRUG CONJUGATE
    Leal, Mauricio
    DRUG METABOLISM REVIEWS, 2012, 44 : 13 - 14
  • [36] Tumor antigen glycosaminoglycan modification regulates antibody-drug conjugate delivery and cytotoxicity
    Christianson, Helena C.
    Menard, Julien A.
    Chandran, Vineesh Indira
    Bourseau-Guilmain, Erika
    Shevela, Dmitry
    Lidfeldt, Jon
    Mansson, Ann-Sofie
    Pastorekova, Silvia
    Messinger, Johannes
    Belting, Mattias
    ONCOTARGET, 2017, 8 (40) : 66960 - 66974
  • [37] EFFICACY OF THE ANTIBODY-DRUG CONJUGATE ABT-414 IN BRAIN TUMOR MODELS
    Muldoon, Leslie
    McConnell, Heather
    Kersch, Cymon
    Neuwelt, Edward
    NEURO-ONCOLOGY, 2017, 19 : 80 - 80
  • [38] Preclinical studies of an anti-HER2 antibody-drug conjugate.
    Koeppen, H
    Dugger, D
    Tibbitts, J
    Leipold, D
    Reynolds, T
    Leach, W
    Slikowski, M
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 8980S - 8980S
  • [39] Characterization of human anti-EpCAM antibodies for developing an antibody-drug conjugate
    Satofuka, Hiroyuki
    Wang, Yayan
    Yamazaki, Kyotaro
    Hamamichi, Shusei
    Fukuhara, Takeshi
    Rafique, Abdur
    Osako, Nana
    Kanazawa, Iori
    Endo, Takeshi
    Miyake, Naomi
    Honma, Kazuhisa
    Nagashima, Yuichi
    Hichiwa, Genki
    Shimoya, Kazuto
    Abe, Satoshi
    Moriwaki, Takashi
    Murakami, Yasufumi
    Gao, Xu
    Kugoh, Hiroyuki
    Oshimura, Mitsuo
    Ito, Yuji
    Kazuki, Yasuhiro
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [40] Anti-tumor activity of antibody drug conjugate targeting aspartate-β-hydroxylase in pancreatic ductal adenocarcinoma
    Nagaoka, Katsuya
    Bai, Xuewei
    Ogawa, Kosuke
    Dong, Xiaoqun
    Zhang, Songhua
    Zhou, Yanmei
    Carlson, Rolf, I
    Jiang, Zhi-Gang
    Fuller, Steve
    Lebowitz, Michael S.
    Ghanbari, Hossein
    Wands, Jack R.
    CANCER LETTERS, 2019, 449 : 87 - 98
12345